Traumatic Brain Injury
Traumatic brain injury (TBI) impacts over 2.5 million people annually in the US. AivoCode has licensed technology from Sanford Burnham Prebys Medical Discovery Institute (SBP) to improve delivery of therapeutic or an imaging payload from systemic circulation to the injured part of the brain.
AivoCode is developing a new approach to TBI therapy by using a novel peptide AC01 which possesses a drug like activity. AC01 when given as repeated intravenous injections during the first days after TBI, strongly reduces the size of a brain lesion. Moreover, preliminary results suggest that there is also some functional improvement after AC01 treatment, particularly in motor functions. Thus, AC01 is potentially useful in limiting the secondary damage in TBI.
Given the limited treatment options for these conditions, our technology has the potential to change the clinical management of TBI.
To read more about this technology, read our article published in the journal Nature Communications.
Brain Targeting Technology
Fluorescently labeled peptide accumulates only in the injured region of the brain.
Independent publications on AivoCode’s targeting platform for targeting injuries of the central nervous system
Han Z, Han Y, Huang X, Ma H, Zhang X, Song J, Dong J, Li S, Yu R, Liu H. A Novel Targeted Nanoparticle for Traumatic Brain Injury Treatment: Combined Effect of ROS Depletion and Calcium Overload Inhibition. Adv Healthc Mater. 2022 Feb 3:e2102256. doi: 10.1002/adhm.202102256. Epub ahead of print. PMID: 35118827.
Li T, Jing P, Yang L, Wan Y, Du X, Wei J, Zhou M, Liu Z, Lin Y, Zhong Z. CAQK modification enhances the targeted accumulation of metformin-loaded nanoparticles in rats with spinal cord injury. Nanomedicine. 2022 Apr;41:102526. doi: 10.1016/j.nano.2022.102526. Epub 2022 Jan 30. PMID: 35104674.
Wang J, Li D, Liang C, Wang C, Zhou X, Ying L, Tao Y, Xu H, Shu J, Huang X, Gong Z, Xia K, Li F, Chen Q, Tang J, Shen Y. Scar Tissue-Targeting Polymer Micelle for Spinal Cord Injury Treatment. Small. 2020 Feb;16(8):e1906415. doi: 10.1002/smll.201906415. Epub 2020 Jan 31. PMID: 32003924.
Wu P, Zhao H, Gou X, Wu X, Zhang S, Deng G, Chen Q. Targeted delivery of polypeptide nanoparticle for treatment of traumatic brain injury. Int J Nanomedicine. 2019 May 31;14:4059-4069. doi: 10.2147/IJN.S202353. PMID: 31213815; PMCID: PMC6549727.
Wang B, Chang M, Zhang R, Wo J, Wu B, Zhang H, Zhou Z, Li Z, Zhang F, Zhong C, Tang S, Yang S, Sun G. Spinal cord injury target-immunotherapy with TNF-α autoregulated and feedback-controlled human umbilical cord mesenchymal stem cell derived exosomes remodelled by CRISPR/Cas9 plasmid. Mater Sci Eng C Mater Biol Appl. 2021 Dec 24:112624. doi: 10.1016/j.msec.2021.112624. Epub ahead of print. PMID: 35525736.
Wang Q, Zhang H, Xu H, Zhao Y, Li Z, Li J, Wang H, Zhuge D, Guo X, Xu H, Jones S, Li X, Jia X, Xiao J. Novel multi-drug delivery hydrogel using scar-homing liposomes improves spinal cord injury repair. Theranostics. 2018 Aug 7;8(16):4429-4446. doi: 10.7150/thno.26717. PMID: 30214630; PMCID: PMC6134929.
Sun G, Zeng S, Liu X, Shi H, Zhang R, Wang B, Zhou C, Yu T. Synthesis and Characterization of a Silica-Based Drug Delivery System for Spinal Cord Injury Therapy. Nanomicro Lett. 2019 Mar 11;11(1):23. doi: 10.1007/s40820-019-0252-6. PMID: 34137964; PMCID: PMC7770885.